Characteristics and outcome of SARS-CoV-2 infection in cancer patients.
Authors:
- Clemence BasseCBClemence Basse
- Vincent ServoisVSVincent Servois
- Maxime FrelautMFMaxime Frelaut
- Aurelien NoretANAurelien Noret
- Audrey BellesoeurABAudrey Bellesoeur
- Pauline MoreauPMPauline Moreau
- Marie-Ange MassianiMMMarie-Ange Massiani
- Anne-Sophie BouyerABAnne-Sophie Bouyer
- Perrine VuagnatPVPerrine Vuagnat
- Sandra MalakSMSandra Malak
- Francois-Clement BidardFBFrancois-Clement Bidard
Preprint
Abstract
Background: Concerns have emerged about the higher risk of fatal COVID-19 in cancer patients. In this paper, we review the experience of a comprehensive cancer center. Methods: A prospective registry was set up at Institut Curie at the beginning of the COVID-19 pandemic. All cancer patients with suspected or proven COVID-19 were entered and actively followed for 28 days. Results: Among 9,842 patients treated at Institut Curie between mid-March and early May 2020, 141 (1.4%) were diagnosed with COVID-19, based on RT-PCR testing and/or CT-scan. In line with our case-mix, breast cancer (40%) was the most common tumor type, followed by hematological and lung malignancies (both 13%). Patients with active cancer therapy or/and advanced cancer accounted for 88% and 69% of patients, respectively. At diagnosis, 79% of patients had COVID-19 related symptoms, with an extent of lung parenchyma involvement ≤50% in 90% of patients. Blood count variations and C-reactive protein elevation were the most common laboratory abnormalities. Antibiotics and antiviral agents were administered in 48% and 7% of patients, respectively. At the time of analysis, 26 patients (18%) have died from COVID-19, and 81 (57%) were cured. Independent prognostic factors at the time of COVID-19 diagnosis associated with death or intensive care unit admission were extent of COVID-19 pneumonia and decreased O2 saturation. Conclusions: COVID-19 incidence and presentation in cancer patients appear to be very similar to those in the general population. The outcome of COVID-19 is primarily driven by the initial severity of infection rather than patient or cancer characteristics.Keywords
All Related Versions
- Published version: JNCI Cancer Spectrum, 5 (1), pkaa090.
This publication has 23 references indexed in Scilit:
- Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York CityAnnals of Oncology, 2020
- SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, ChinaJAMA Oncology, 2020
- Caring for Patients With Cancer During the COVID-19 Outbreak in ItalyJAMA Oncology, 2020
- Managing COVID-19 in the oncology clinic and avoiding the distraction effectAnnals of Oncology, 2020
- Impact de l’épidémie de COVID-19 sur les demandes de prise en charge initiale pour cancer du seinBulletin du Cancer, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, ChinaAnnals of Oncology, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020